Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
September 02 2020 - 3:01PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Jounce management will participate in fireside chats at three
upcoming investor conferences in September:
- Baird 2020 Global Healthcare Conference at
12:50 p.m. ET on Wednesday, September 9, 2020.
- 2020 Wells Fargo Virtual Healthcare Conference
at 3:20 p.m. ET on Thursday, September 10, 2020.
- H.C. Wainwright 22nd Annual Healthcare
Conference at 3:00 p.m. ET on Monday, September 14,
2020.
A live webcast of each presentation will be available by
visiting "Events & Presentations" in the Investors and Media
section of the company's website at www.jouncetx.com. A replay of
the webcast will be archived for 30 days following the
presentation.
About Jounce Therapeutics:Jounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development-stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s lead product candidate, vopratelimab, is a
monoclonal antibody that binds to and activates ICOS, and is
currently being studied in the EMERGE Phase 2 trial. Vopratelimab
will also be evaluated in the Phase 2 SELECT trial in combination
with Jounce’s internal investigational PD-1 inhibitor, JTX-4014, in
biomarker selected patients using TISvopra. Jounce’s next clinical
candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown
to reprogram immune-suppressive tumor associated macrophages to an
anti-tumor state. Additionally, Jounce has agreed to exclusively
license worldwide rights to JTX-1811, a monoclonal antibody
targeting CCR8 and designed to selectively deplete T regulatory
cells in the tumor microenvironment, to Gilead Sciences. For more
information, please visit www.jouncetx.com.
Investor and Media Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Oct 2023 to Oct 2024